Interactive Psychopharmacologic Effects of Alcohol and Nicotine in Humans
Information source: Yale University
Information obtained from ClinicalTrials.gov on November 03, 2008 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Alcohol Consumption; Tobbaco Use
Intervention: Nicotine (Drug); Ethanol (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Yale University Official(s) and/or principal investigator(s): Edward B Perry, M.D., Principal Investigator, Affiliation: Yale University
Overall contact: Vanessa Bufis, Phone: 203-932-5711, Ext: 2526, Email: vanessa.bufis@yale.edu
Summary
The purpose of this study is to characterize the interactive psychopharmacologic effects of
acute intravenous (IV) alcohol and nicotine administration in male and female smokers and
nonsmokers who use alcohol. The IV alcohol administration will be accomplished using the
breath alcohol (BrAc) clamp method.
The primary hypothesis is that nicotine will attenuate the disruptive effects of alcohol on
cognitive inhibition as measured by the Continuous Performance Task-Identical Pairs (CPT-IP)
task, processing speed and attention as measured by the CPT-IP, and working memory as
measured by the Rey Auditory Verbal Learning Task.
The secondary, exploratory hypothesis is that nicotine will attenuate the disruptive effects
of alcohol on impulse control (risky decision-making) as measured by the Balloon Analog Risk
Task. We also hypothesize that administration of nicotine will decrease alcohol-induced
inhibitory effects as measured by the Visual Analog Scales of Mood States and the Biphasic
Alcohol Effects Scale, and that alcohol will increase nicotine craving and withdrawal as
measured by the QSU-Brief.
Clinical Details
Official title: Interactive Psychopharmacologic Effects of Alcohol and Nicotine in Humans
Study design: Other, Double Blind (Subject, Investigator, Outcomes Assessor), Single Group Assignment
Primary outcome: Continuous Performance Task-Identical PairsRey Auditory Verbal Learning Task
Secondary outcome: Balloon Analog Risk TaskVisual Analog Scales of Mood States Biphasic Alcohol Effects Scale Questionnaire of Smoking Urges
Eligibility
Minimum age: 21 Years.
Maximum age: 50 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Male and female;
2. between the ages of 21 and 50 years;
3. medically and neurologically healthy on the basis of history, physical examination,
EKG, screening laboratories (CBC w/ differential, TSH, free-T4, AST, ALT, GGT, BUN,
creatinine, calcium, phosphorous, magnesium, total protein, albumin, electrolytes,
VDRL, urinalysis, serum beta-HCG for women of childbearing potential);
4. currently smoking cigarettes (no more than 1 pack per day; subjects who smoke pipes
and/or cigars only will be excluded) and not interested in stopping smoking or not
currently smoking but have tried cigarettes in the past;
5. have had at least 4 drinks on at least 2 occasions in the past year and are not
interested in stopping drinking;
6. absence of current and past substance abuse, with the exception of alcohol abuse on
the basis of history and urine toxicology and breath alcohol levels at screening and
on each test day.
Exclusion Criteria:
1. Present or past DSM-IV psychiatric and substance abuse/dependence, with the exception
of alcohol, diagnosis by history and psychiatric evaluation including a Structured
Clinical Interview for DSM-IV Non-Patient (SCID-NP)(45);
2. Subjects who meet criteria for alcohol abuse and express an interest in stopping
alcohol use and/or express an interest in treatment or are currently enrolled in
treatment for alcoholism, or have sought treatment in the last 6 months;
3. history of counseling or psychotherapy, except family therapy centered around another
family member or marital therapy;
4. for women of childbearing potential: positive pregnancy test or refusal to use
contraception during the study;
5. alcohol and/or nicotine naïve;
6. history of psychosis in first degree relative.
Locations and Contacts
Vanessa Bufis, Phone: 203-932-5711, Ext: 2526, Email: vanessa.bufis@yale.edu
VA Connecticut Healthcare System, West Haven Campus, West Haven, Connecticut 06516, United States; Recruiting Edward B Perry, M.D., Principal Investigator
Additional Information
Starting date: January 2007
Ending date: July 2009
Last updated: February 4, 2008
|